| Market Cap | 26.72M | P/E | - | EPS this Y | 24.00% | Ern Qtrly Grth | - |
| Income | -24.83M | Forward P/E | -1.00 | EPS next Y | 45.10% | 50D Avg Chg | -25.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -54.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 0.08 | Shares Outstanding | 10.75M | 52W Low Chg | 9.00% |
| Insider Own | 26.51% | ROA | -115.97% | Shares Float | 7.94M | Beta | 1.26 |
| Inst Own | 4.76% | ROE | - | Shares Shorted/Prior | 426.49K/474.64K | Price | 0.38 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 387,188 | Target Price | 31.50 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 225,391 | Change | -4.83% |
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
| Ascendiant Capital | Buy | Sep 12, 24 |
| HC Wainwright & Co. | Buy | Aug 5, 24 |
| Ascendiant Capital | Buy | Jun 7, 24 |
| HC Wainwright & Co. | Buy | May 25, 23 |
| HC Wainwright & Co. | Buy | Feb 2, 23 |
| Ascendiant Capital | Buy | Nov 9, 22 |
| HC Wainwright & Co. | Buy | Jun 30, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gorovitz Aaron | Director Director | Aug 30 | Buy | 0.3199 | 35,000 | 11,196 | 105,000 | 09/11/23 |
| Hurvitz Chaim | Director Director | Aug 30 | Buy | 0.2875 | 70,000 | 20,125 | 570,000 | 09/11/23 |
| Javitt Jonathan C | Chief Scientist Chief Scientist | Aug 23 | Buy | 0.33 | 100,000 | 33,000 | 446,332 | 08/24/23 |
| Javitt Jonathan C | Chief Scientist Chief Scientist | Aug 22 | Buy | 0.322 | 200,000 | 64,400 | 346,332 | 08/23/23 |
| Willard Stephen H | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Dec 16 | Buy | 1.17 | 50,000 | 58,500 | 50,000 | 12/19/22 |
| VAN VOORHEES SETH | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Dec 16 | Buy | 1.10 | 30,000 | 33,000 | 46,337 | 12/19/22 |
| VAN VOORHEES SETH | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 25 | Buy | 1.11 | 16,337 | 18,134 | 16,337 | 12/19/22 |
| Javitt Daniel C. | 10% Owner 10% Owner | Nov 29 | Sell | 1.5 | 22,171 | 33,256 | 9,634,793 | 12/01/22 |
| Flynn Patrick John | Director Director | Nov 28 | Buy | 1.25 | 11,750 | 14,688 | 1,750 | 11/29/22 |
| VAN VOORHEES SETH | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Nov 25 | Buy | 1.11 | 16,337 | 18,134 | 16,377 | 11/28/22 |
| Javitt Daniel C. | 10% Owner 10% Owner | Nov 16 | Sell | 1.04 | 166,737 | 173,406 | 9,656,964 | 11/18/22 |
| Javitt Daniel C. | 10% Owner 10% Owner | Nov 11 | Sell | 1.0063 | 49,200 | 49,510 | 9,823,701 | 11/15/22 |
| Javitt Daniel C. | 10% Owner 10% Owner | Jul 29 | Sell | 1.0094 | 784,063 | 791,433 | 9,872,901 | 08/02/22 |
| Javitt Daniel C. | 10% Owner 10% Owner | Jun 03 | Sell | 0.67 | 445,712 | 298,627 | 12,656,964 | 06/07/22 |
| Javitt Jonathan C | Chief Scientist Chief Scientist | Jun 01 | Buy | 58.00 | 100,000 | 5,800,000 | 146,332 | 06/02/22 |